Fast Separation of Monoclonal Antibody and Dimer by SEC with Agilent Bio SEC

 

Similar PDF

Toggle
Helpful ‘Hints’ for Protein SEC Success
2021|Agilent Technologies|Presentations
Helpful ‘Hints’ for Protein SEC Success Jean Lane Applications Engineer LC columns and consumables technical support May 27, 20201 Outline for Talk Getting started • SEC definition, common terminology, and why use it? • Considerations for selecting an SEC column…
Key words
hints, hintshelpful, helpfulsec, secsuccess, successprotein, proteinpore, poreadvancebio, advancebiosize, sizebuffer, bufferexclusion, exclusionmobile, mobilephase, phasecolumn, columndimer, dimervolume
Agilent Biocolumns Aggregate/Fragment Analysis Application Compendium Contents Background 2 Getting Started 3 How to Guide - Size Exclusion Chromatography for Biomolecule Analysis - 5991-3651EN 4 Featured Application Notes Elevate Your mAb Aggregate Analysis - 5994-2709EN 1 22 22 High-Resolution, High-Throughput…
Key words
return, returnsection, sectionmau, maucontents, contentssec, secinsulin, insulinmin, minsize, sizeprotein, proteinmonomer, monomeradvancebio, advancebiotime, timeaggregates, aggregatesexclusion, exclusionaggregate
[ APPLICATION NOTEBOOK ] SIZE-EXCLUSION CHROMATOGRAPHY (SEC) OF PEPTIDES, PROTEINS, AND AAVs [ SIZE-EXCLUSION CHROMATOGRAPHY ] [ SIZE-EXCLUSION CHROMATOGRAPHY ] Introduction Gel-permeation chromatography (GPC), size-exclusion chromatography (SEC), and gel-filtration chromatography (GFC) are commonly used terms to describe a liquid chromatographic…
Key words
sec, secexclusion, exclusionsize, sizeuplc, uplcacquity, acquityprotein, proteinchromatography, chromatographyaggregates, aggregateshplc, hplcdispersion, dispersionmonomer, monomercolumn, columnantibody, antibodyigg, igghmws
Mobile Phase Optimization in SEC Method Development
2018|Agilent Technologies|Applications
Application Note Pharma & Biopharma Mobile Phase Optimization in SEC Method Development Author Richard Hurteau Agilent Technologies, Inc., Wilmington, DE, USA Abstract Aggregation of monoclonal antibody (mAb) products has an adverse effect on their efficacy as therapeutic agents. Size exclusion…
Key words
mau, maumin, minigg, iggphosphate, phosphatekda, kdainsulin, insulinaggregation, aggregationbuffer, bufferadc, adccytochrome, cytochromeproteins, proteinscolumns, columnsnriu, nriutherapeutic, therapeuticpeak
Other projects
Follow us
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o., all rights reserved.